Biodexa Pharmaceuticals PLC
BDRX
查看详细走势图
4.750USD
-1.550-24.60%
收盘 12/12, 16:00（美东）报价延迟15分钟
29.43B总市值
27.25市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-24.60%
5天
-5.75%
1月
-7.05%
6月
-55.61%
今年开始到现在
-88.27%
1年
-88.69%
查看详细走势图
TradingKey Biodexa Pharmaceuticals PLC股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Biodexa Pharmaceuticals PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
180.000
目标均价
+3813.04%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Biodexa Pharmaceuticals PLC亮点
亮点风险
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Biodexa Pharmaceuticals PLC简介
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
公司代码BDRX
公司Biodexa Pharmaceuticals PLC
CEOStamp (Stephen A)
网址https://www.biodexapharma.com/
常见问题
Biodexa Pharmaceuticals PLC(BDRX)的当前股价是多少？
Biodexa Pharmaceuticals PLC(BDRX)的当前股价是 4.750。
Biodexa Pharmaceuticals PLC的股票代码是什么？
Biodexa Pharmaceuticals PLC的股票代码是BDRX。
Biodexa Pharmaceuticals PLC股票的52周最高点是多少？
Biodexa Pharmaceuticals PLC股票的52周最高点是92.000。
Biodexa Pharmaceuticals PLC股票的52周最低点是多少？
Biodexa Pharmaceuticals PLC股票的52周最低点是3.580。
Biodexa Pharmaceuticals PLC的市值是多少？
Biodexa Pharmaceuticals PLC的市值是29.43B。
Biodexa Pharmaceuticals PLC的净利润是多少？
Biodexa Pharmaceuticals PLC的净利润为-5.73M。
现在Biodexa Pharmaceuticals PLC(BDRX)的股票是买入、持有还是卖出？
根据分析师评级，Biodexa Pharmaceuticals PLC(BDRX)的总体评级为--，目标价格为180.000。
Biodexa Pharmaceuticals PLC(BDRX)股票的每股收益（EPS TTM）是多少
Biodexa Pharmaceuticals PLC(BDRX)股票的每股收益（EPS TTM）是0.174。
相关品种
